Neuro Immunoassay Market Outlook (2023 to 2033)

The neuro immunoassay market is projected to be valued at US$ 5,303.1 million by 2033, up from US$ 2,616.1 million in 2023, increasing at a CAGR of 7.3% during the forecast period.

Immunoassays (IAs) are crucial in several bioanalytical settings like biopharmaceutical analysis, clinical diagnostics, security, environmental monitoring, and food testing. It is a chemical test done for the detection and quantifying of a particular substance with the use of an immunological reaction. Neuro Immunoassay is a test method that is swift and precise and can be used on-site and in the laboratory to identify specific molecules.

The demand for neuro immunoassays is increasing as these procedures rely on the technique of an antibody to bind to a particular structure of a molecule. Immunoassays can be either quantitative or qualitative. The latter is used to ascertain the concentration of an analyte, measuring the strength of a signal created by indicator reactions, and quantitatively used in situations such as determining if a woman is pregnant, which can usually be diagnosed within 2 days of fertilization.

The global demand for neuro immunoassay is surging as they have been broadly used for pharmaceutical analysis, such as pharmacokinetic and bioequivalence of drug discovery, diagnosis of disease, and drug monitoring.

Immunoassays are of various formats like monoclonal, polyclonal sandwich assays, competitive inhibition assays, antigen-down immunoassays, and rapid assays. The importance of neuro immunoassay in the pharmaceutical industry is owing to its fundamental specificity, sensitivity for the analysis of biological samples, and high throughput.

The market growth is also anticipated to be driven by the increasing approval and introduction of immunoassay instruments. A notable example is the Food and Drug Administration's (FDA) approval in December 2022 of Roche's AD assay, which utilizes the Cobas immunoassay analyzer. Likewise, in July 2022, the FDA designated the Elecsys Amyloid Plasma Panel as a breakthrough device, enabling the measurement of Alzheimer's disease biomarkers from a blood sample.

Attributes Details
Historical Value (2022) US$ 2,456.1 million
Current Year Value (2023) US$ 2,616.1 million
Expected Forecast Value (2033) US$ 5,303.1 million
Historical CAGR (2018 to 2022) 6.2%
Projected CAGR (2023 to 2033) 7.3%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Key Drivers Steering the Neuro Immunoassay Market Ahead

Prevalence of Neurodegenerative Diseases:

The primary market driving factor contributing to the growth of the neuro immunoassay market is the increasing prevalence of neurodegenerative diseases. Expanding biotechnology, more investments in neuroscience research and pharmaceutical industries are some of the other crucial elements promoting the market growth of neuro immunoassay.

Rising Geriatric Population:

The geriatric population is increasing, which is resulting in more cases of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and Huntington’s disease. This is said to promote the growth of this market, and thereby, the market share of neuro immunoassay is said to propel during the forecast period.

Technological Advancement:

Technological advancement coupled with rising awareness pertaining to the application of immunoassay in monitoring and diagnosis purpose of neuro diseases are said to support the market of neuro immunoassay by surging its demand in the market.

Importunity for High-Quality Antibodies:

Rising demand for superior quality antibodies owing to identifying the novel potential drug target, the structural protein in the brain, signaling molecules along with developing recognition of the anti-brain specific autoantibodies’ role in human diseases are said to promote the neuro immunoassay market growth.

Extensive R&D Investments:

There is an alarmingly growing number of research and abundant investments done towards neuroscience research. This has encouraged several medical and healthcare giants along with the Governments to promote sanctions towards various research and development, thereby boosting the neuro immunoassay market growth.

Growth Impeders in the Neuro Immunoassay Market

Besides the various market promoting factors, some factors such as strict regulations by the government, lack of experience in using these techniques, and higher costs associated with the procedure are anticipated to restrict the neuro immunoassay market growth.

Moreover, quality and concerns pertaining to the cost of the production of antibodies will also hinder the market growth during the forecast period.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What is the Regional Outlook for the North American Neuro Immunoassay Market?

By considering the present neuro immunoassay market situation across the globe, North America is anticipated to dominate the global market and attribute to the biggest market share in terms of revenue owing to better government initiatives and better economic conditions.

North America is said to hold 33.8% of the total neuro immunoassay market share during the forecast period. In North America, a country like the United States is said to lead, and the neuro immunoassay market is driven by growing molecular diagnosis.

What is the Regional Outlook for the European Neuro Immunoassay Market?

The European region accounts for 29.6% of the neuro immunoassay market share, owing to its high disposable income and increasing demand for affordable treatment and cost-effective therapies.

In Europe, owing to the rising trend toward racing competitors and increasing awareness amongst the population. The focus of stakeholders on research projects involving proteins, associated biomolecules, and genes are the crucial factors that are promoting the neuro immunoassay market growth in Europe.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Country-wise Insight

Countries 2022 Value Share in Global Market
United States 30.4%
Germany 6.2%
Japan 3.6%

Are Neuro Immunoassays Revolutionizing Neurological Disorder Diagnoses in the United States?

The United States holds a significant share in the global neuro immunoassay industry. The growth in the United States neuro immunoassay market can be attributed to several factors, including

  • high prevalence of neurological diseases
  • growing customer awareness regarding the use of biomarkers in diagnosing neurological disorders
  • increased healthcare expenditure
  • the availability of technologically advanced products
  • proactive government initiatives
  • improved healthcare infrastructure

The United States is witnessing an increased prevalence of autoimmune diseases. As per the Parkinson's Foundation, the number of individuals living with Parkinson's disease in the United States was around one million in 2022. It is projected that this figure could increase to 1.2 million by 2030. Parkinson's disease is the second-most prevalent neurodegenerative disorder, following Alzheimer's disease. There is a growing focus on understanding and diagnosing Alzheimer's and Parkinson's diseases in the United States. Therefore, the high prevalence of neurological diseases is expected to contribute to market growth significantly.

Key players are strategically taking initiatives to expand their market share through the development of advanced biomarker technology for diagnostics and treatment research. In December 2022, the United States FDA approved two immunoassays developed by F. Hoffmann-La Roche Ltd.: Elecsys Phospho-Tau (181P) CSF (pTau181) and Elecsys beta-Amyloid (1-42) CSF II (Abeta42). These assays enable the measurement of two important biomarkers, tau proteins, and beta-amyloid, in adult patients, thereby aiding in the confirmation of Alzheimer's disease diagnosis. In March 2022, Quanterix entered into a licensing agreement with Eli Lilly and Company. This agreement allows Quanterix to utilize pTau 217 for near-term clinical research purposes and for long-term in vitro diagnostic (IVD) applications.

What Innovative Technologies are Shaping the Neuro Immunoassay Market in Germany?

The incidence of neurological disorders in Germany is increasing. Neurological disorders include brain aneurysms, brain tumors, epilepsy, memory disorders, multiple sclerosis, Parkinson's disease, peripheral neuropathy, and spinal cord tumors. The Germany neuro immunoassay market is expected to grow as a result. According to the German Brain Tumor Association, 25% of cancer diagnoses in young individuals involve tumors in the brain and central nervous system.

Germany has a significant burden of neurological disorders, with conditions like Alzheimer's disease and Parkinson's disease affecting a large portion of the population. The Alzheimer's Association reported that over 1.6 million people in Germany had Alzheimer's Disease in 2021. The large number of Alzheimer's patients indicates a significant market opportunity in the country. In February 2021, STADAPHARM GmbH, based in Germany, launched a new triple combination product for advanced Parkinson's disease treatment. The product incorporates modern pump technology. The introduction of such products is expected to contribute to the market's growth.

What Impact is the Aging Population Having on Japan Neuro Immunoassay Market?

Japan has one of the world's highest proportions of elderly citizens, according to World Bank statistics published in July 2022. This leads to a significant burden of age-related neurological disorders. The aging population in Japan creates a substantial demand for accurate diagnostic tools. This demand, in turn, drives the growth of the neuro immunoassay market. The Japan government has implemented various initiatives to promote healthcare innovation and improve patient care.

A study published in the Journal of Alzheimer's Diseases in March 2021 revealed predictions for Japan's dementia cases. It is estimated that between 6.5 million to 7 million people could have dementia in 2025, and the numbers could increase from 8.5 million to 11.5 million by 2060. Additionally, in Japan, it is reported that 50-75% of dementia cases are attributed to Alzheimer's disease.

Companies are striving to innovate and expand their presence in the market. An example of this is the marketing approval obtained by Sysmex Corporation in Japan in December 2022 for their HISCL β-Amyloid Assay Kits. These kits are designed to detect and measure amyloid beta levels in blood samples, aiding in the diagnosis of Alzheimer's disease (AD).

Countries Value CAGR (2023 to 2033)
United Kingdom 6.3%
China 8.5%
India 7.3%

What Role Does the NHS Play in Advancing Neuro Immunoassays in the United Kingdom?

About one out of every six individuals in the United Kingdom is affected by at least one neurological condition, and it is estimated that around 600,000 people receive a diagnosis each year. The United Kingdom is experiencing a shift toward personalized medicine. Neuro immunoassays are crucial in identifying specific biomarkers and tailoring treatments accordingly. This trend is driving the adoption of advanced immunoassay techniques. The United Kingdom neuro immunoassay market growth is expected to be fueled by key players engaged in the development of neurological biomarkers.

The market in the United Kingdom benefits from collaborations between industry players and the National Health Service. For example, in November 2021, the Department of Health and Social Care announced a substantial investment of US$ 456.62 million in neurodegenerative research in the United Kingdom. Additionally, the utilization of clinical data informatics platforms by productive research organizations is projected to play a role in propelling the United Kingdom neuro immunoassay market growth during the forecast period.

What Are the Key Drivers Behind China's Surge in Neuro Immunoassay Market?

China has the world's largest population, exceeding 1.45 billion people. The aging population in China is especially susceptible to neurological disorders. This vulnerability emphasizes the importance of advanced diagnostic tools such as neuro immunoassays. In China, the concept of precision medicine has gained significant traction. This has resulted in the adoption of personalized approaches to diagnose and treat neurological disorders. The country has experienced a considerable rise in healthcare expenditure. This increase has facilitated patient access to advanced diagnostic procedures.

The prevalence of Parkinson's disease among individuals aged 65 years or older is around 1.7%. It is projected that about 1.7 million individuals in China aged 55 years or older are affected by Parkinson's disease. These findings indicate that the prevalence of Parkinson's disease in China is comparable to that observed in developed countries. On the other hand, the population of individuals affected by Alzheimer's disease in China is about six million. The prevalence of dementia among different age groups is estimated to be 5% among 65-year-olds, 11.5% among 75-year-olds, and 30% among 85-year-olds.

How Large is the Patient Pool for Neuro Immunoassay Tests in India?

India has witnessed a significant increase in the prevalence of neurological disorders, primarily due to factors like

  • an aging population
  • sedentary lifestyles
  • changing environmental conditions

The country has witnessed remarkable advancements in the field of neuro immunoassay technology. The Indian government has launched several initiatives to address the rising burden of neurological disorders. With more than 1.48 billion people, India now boasts the largest population in the world. This provides a significant market opportunity for neuro immunoassay tests.

India neuro immunoassay market growth is also expected to be driven by the expansion of the pharmaceutical and biotechnology industries during the forecast period. A noteworthy example is the projected triple growth of the domestic market in India, as stated in the Indian Economic Survey 2021. Ranked among the top five global pharmaceutical intermediary manufacturers, India possesses significant prowess in the pharmaceutical industry. Furthermore, India boasts the maximum number of production companies approved by the United States FDA outside of the United States.

How is the Start-up Ecosystem in the Neuro Immunoassay Market?

Multiple neuro immunoassay market opportunities for growth are being opened as various neuro immunoassay market manufacturers are focusing on additional expenditure on research and development activities to create advanced immunoassay therapies. It has been predicted that several new entrants will be focusing on the neuro immunoassay market in the future.

One of the key potential start-ups is Nomic, a Canadian start-up that collected $17 Mn to enhance its automated, high-throughput ELISA platform. This start-up focuses on giving a 21st-century upgrade to decades-old, hand-performed ELISA test.

Who are the Key Players in the Neuro Immunoassay Market?

Some of the key players in the neuro immunoassay market are: Intrinsic LifeSciences, Danaher Corporation (Beckman Coulter), Becton Dickinson and Company, Akers Biosciences, Inc., Abbott Laboratories, Inc, EDP Biotech Corporation, Hologic (Gen-Probe), Biomérieux, and others.

Recent Development in the Neuro Immunoassay Market:

  • In May 2023, Beckman Coulter introduced a new immunoassay analyzer known as DxI 9000 Access. This innovative analyzer has the capability to perform up to 215 tests per hour per square meter (tests/h/m²).
  • In March 2023, the release of the Lumipulse G NfL CSF and Lumipulse G NfL Blood tests was officially announced by H.U. Group Holdings Inc. and Fujirebio. The completely automated random-access LUMIPULSE® G immunoassay systems are intended to work with these assays. They utilize CLEIA (chemiluminescent enzyme immunoassay) technology. Neurofilament light (NfL) can potentially be quantitatively measured using the tests in human plasma/serum and cerebral spinal fluid (CSF), respectively.
  • In January 2023, the United States FDA granted approval for Leqembi (lecanemab-irmb). The approval was obtained through the Accelerated Approval pathway.. It belongs to a new category of medications that target the fundamental pathophysiology of the Alzheimer's disease. This approval marks a significant advancement in the ongoing efforts to effectively treat Alzheimer's disease.
  • In September 2022, QIAGEN partnered with Neuron23. Their collaboration aims to develop an assay for detecting biomarkers discovered by Neuron23. This assay is intended to predict the responsiveness of Parkinson's disease to the LRRK2 inhibitor.
  • In July 2022, Labcorp launched a new test. This test offers concrete proof of neuronal damage and neurodegeneration. The Neurofilament Light Chain (NFL) blood test is the first of its kind. It enables medical professionals to spot and confirm neurodegenerative disease symptoms. With this test, physicians can offer a more effective and efficient path to diagnosis and treatment for patients.
  • In June 2022, Becton Dickinson and Company which is global leader in medical technology, and a leading private equity firm Frazier Healthcare Partners who focus on healthcare sector - announced an agreement for the former to acquire Parata Systems which is an innovative provider of pharmacy automation solutions for $1.525 billion.

Segment Wise Outlook for Neuro Immunoassay Market

Segment 2022 Value Share in Global Market
ELISA Technology 39.90%
Reagents and Kits 62.30%

How does ELISA outshine other Technologies in the Neuro Immunoassay Market?

Based on the technology, in 2022, the ELISA segment led the market for neuro immunoassay and was accountable for a larger revenue share. A few of the key advantages of this method are quantitative results, decreased assay time, and the need for limited antisera for analysis.

ELISA (Enzyme-Linked Immunosorbent Assay) has traditionally dominated the market due to its sensitivity, specificity, established methodology, wide analyte range, cost-effectiveness, and ability to provide quantitative results. With its high sensitivity and specificity, ELISA can detect low concentrations of analytes relevant to neurological disorders. The methodology is well-documented, and commercially available ELISA kits exist for specific analytes. This makes it accessible to researchers and clinicians. Newer technologies may challenge ELISA's dominance in the future. However, ELISA remains a reliable choice for neuro immunoassays. It offers accurate results in quantifying biomarkers. ELISA is also cost-effective compared to some advanced immunoassay technologies.

Why Are Reagents and Kits the Go-to Choice in the Neuro Immunoassay Market?

In the product segment, in 2022, reagents and kits segment led the global neuro immunoassay market and is said to dominate during the forecast period. This is due to rising demand for immunoassay reagents and kits for diagnosis purposes as there is rising cases of autoimmune and infectious diseases.

Reagents and kits are essential components required for accurately detecting and quantifying biomarkers in neuro immunoassays. They offer various applications, providing customizable solutions for different biomarkers and assay formats. Reagents and kits also ensure standardization and quality control, allowing for reproducible results. Their convenience and time efficiency make them preferred choices, simplifying the workflow for researchers and clinicians. Additionally, the increasing demand for neuro immunoassays, driven by the rising prevalence of neurological disorders, contributes to the dominance of this segment in the market.

Key Segments of the Neuro Immunoassay Market

By Technology:

  • Radioimmunoassays (RIA)
  • Polymerase Chain Reaction (PCR)
  • ELISA
  • Western Blot
  • Rapid Tests
  • ELISPOT

By Product Type:

  • Reagents and Kits
  • Analysers

By Application:

  • Alzheimer’s Disease
  • Parkinson’s Disease
  • Huntington’s Disease
  • Amyotrophic Lateral Sclerosis (ALS)
  • Spinal Muscular Atrophy (SMA)

By End User:

  • Hospitals
  • Clinics
  • Academic Organizations
  • Biopharmaceutical Companies
  • Pharmaceutical Companies
  • Others

By Region:

  • North America
  • Latin America
  • Asia Pacific
  • Middle East and Africa
  • Europe

Frequently Asked Questions

How Big is the Neuro Immunoassay Market?

The market is valued at US$ 2,616.1 million in 2023.

Who are the Prominent Neuro Immunoassay Market Players?

Abbott Laboratories, Inc, EDP Biotech Corporation, Hologic are the prominent market players.

What is the Growth Potential of the Neuro Immunoassay Market?

The market is expected to witness a a CAGR of 7.3% through 2033.

What is the Expected Market Size by 2033?

The market is predicted to be worth US$ 5,303.1 million by 2033.

How is the Historical Performance of the Market?

From 2018 to 2022, the market held a CAGR of 6.2%.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity 

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Technology

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Technology, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Technology, 2023 to 2033

        5.3.1. Radioimmunoassays (RIA)

        5.3.2. Polymerase Chain Reaction (PCR)

        5.3.3. ELISA

        5.3.4. Western Blot

        5.3.5. Rapid Tests

        5.3.6. ELISPOT

    5.4. Y-o-Y Growth Trend Analysis By Technology, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Technology, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product Type

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Product Type, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product Type, 2023 to 2033

        6.3.1. Reagents and Kits

        6.3.2. Analysers

    6.4. Y-o-Y Growth Trend Analysis By Product Type, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Product Type, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application 

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Application, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2023 to 2033

        7.3.1. Alzheimer’s Disease

        7.3.2. Parkinson’s Disease

        7.3.3. Huntington’s Disease

        7.3.4. Amyotrophic Lateral Sclerosis (ALS)

        7.3.5. Spinal Muscular Atrophy (SMA)

    7.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User

    8.1. Introduction / Key Findings

    8.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022

    8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033

        8.3.1. Hospitals

        8.3.2. Clinics

        8.3.3. Academic Organizations

        8.3.4. Biopharmaceutical Companies

        8.3.5. Pharmaceutical Companies

        8.3.6. Others

    8.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022

    8.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033

9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    9.1. Introduction

    9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        9.3.1. North America

        9.3.2. Latin America

        9.3.3. Western Europe

        9.3.4. Eastern Europe

        9.3.5. South Asia and Pacific

        9.3.6. East Asia

        9.3.7. Middle East and Africa

    9.4. Market Attractiveness Analysis By Region

10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. USA

            10.2.1.2. Canada

        10.2.2. By Technology

        10.2.3. By Product Type

        10.2.4. By Application 

        10.2.5. By End User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Technology

        10.3.3. By Product Type

        10.3.4. By Application 

        10.3.5. By End User

    10.4. Key Takeaways

11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Brazil

            11.2.1.2. Mexico

            11.2.1.3. Rest of Latin America

        11.2.2. By Technology

        11.2.3. By Product Type

        11.2.4. By Application 

        11.2.5. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Technology

        11.3.3. By Product Type

        11.3.4. By Application 

        11.3.5. By End User

    11.4. Key Takeaways

12. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Germany

            12.2.1.2. UK

            12.2.1.3. France

            12.2.1.4. Spain

            12.2.1.5. Italy

            12.2.1.6. Rest of Western Europe

        12.2.2. By Technology

        12.2.3. By Product Type

        12.2.4. By Application 

        12.2.5. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Technology

        12.3.3. By Product Type

        12.3.4. By Application 

        12.3.5. By End User

    12.4. Key Takeaways

13. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. Poland

            13.2.1.2. Russia

            13.2.1.3. Czech Republic

            13.2.1.4. Romania

            13.2.1.5. Rest of Eastern Europe

        13.2.2. By Technology

        13.2.3. By Product Type

        13.2.4. By Application 

        13.2.5. By End User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Technology

        13.3.3. By Product Type

        13.3.4. By Application 

        13.3.5. By End User

    13.4. Key Takeaways

14. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. India

            14.2.1.2. Bangladesh

            14.2.1.3. Australia

            14.2.1.4. New Zealand

            14.2.1.5. Rest of South Asia and Pacific

        14.2.2. By Technology

        14.2.3. By Product Type

        14.2.4. By Application 

        14.2.5. By End User

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Technology

        14.3.3. By Product Type

        14.3.4. By Application 

        14.3.5. By End User

    14.4. Key Takeaways

15. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. China

            15.2.1.2. Japan

            15.2.1.3. South Korea

        15.2.2. By Technology

        15.2.3. By Product Type

        15.2.4. By Application 

        15.2.5. By End User

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Technology

        15.3.3. By Product Type

        15.3.4. By Application 

        15.3.5. By End User

    15.4. Key Takeaways

16. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        16.2.1. By Country

            16.2.1.1. GCC Countries

            16.2.1.2. South Africa

            16.2.1.3. Israel

            16.2.1.4. Rest of MEA

        16.2.2. By Technology

        16.2.3. By Product Type

        16.2.4. By Application 

        16.2.5. By End User

    16.3. Market Attractiveness Analysis

        16.3.1. By Country

        16.3.2. By Technology

        16.3.3. By Product Type

        16.3.4. By Application 

        16.3.5. By End User

    16.4. Key Takeaways

17. Key Countries Market Analysis

    17.1. USA

        17.1.1. Pricing Analysis

        17.1.2. Market Share Analysis, 2022

            17.1.2.1. By Technology

            17.1.2.2. By Product Type

            17.1.2.3. By Application 

            17.1.2.4. By End User

    17.2. Canada

        17.2.1. Pricing Analysis

        17.2.2. Market Share Analysis, 2022

            17.2.2.1. By Technology

            17.2.2.2. By Product Type

            17.2.2.3. By Application 

            17.2.2.4. By End User

    17.3. Brazil

        17.3.1. Pricing Analysis

        17.3.2. Market Share Analysis, 2022

            17.3.2.1. By Technology

            17.3.2.2. By Product Type

            17.3.2.3. By Application 

            17.3.2.4. By End User

    17.4. Mexico

        17.4.1. Pricing Analysis

        17.4.2. Market Share Analysis, 2022

            17.4.2.1. By Technology

            17.4.2.2. By Product Type

            17.4.2.3. By Application 

            17.4.2.4. By End User

    17.5. Germany

        17.5.1. Pricing Analysis

        17.5.2. Market Share Analysis, 2022

            17.5.2.1. By Technology

            17.5.2.2. By Product Type

            17.5.2.3. By Application 

            17.5.2.4. By End User

    17.6. UK

        17.6.1. Pricing Analysis

        17.6.2. Market Share Analysis, 2022

            17.6.2.1. By Technology

            17.6.2.2. By Product Type

            17.6.2.3. By Application 

            17.6.2.4. By End User

    17.7. France

        17.7.1. Pricing Analysis

        17.7.2. Market Share Analysis, 2022

            17.7.2.1. By Technology

            17.7.2.2. By Product Type

            17.7.2.3. By Application 

            17.7.2.4. By End User

    17.8. Spain

        17.8.1. Pricing Analysis

        17.8.2. Market Share Analysis, 2022

            17.8.2.1. By Technology

            17.8.2.2. By Product Type

            17.8.2.3. By Application 

            17.8.2.4. By End User

    17.9. Italy

        17.9.1. Pricing Analysis

        17.9.2. Market Share Analysis, 2022

            17.9.2.1. By Technology

            17.9.2.2. By Product Type

            17.9.2.3. By Application 

            17.9.2.4. By End User

    17.10. Poland

        17.10.1. Pricing Analysis

        17.10.2. Market Share Analysis, 2022

            17.10.2.1. By Technology

            17.10.2.2. By Product Type

            17.10.2.3. By Application 

            17.10.2.4. By End User

    17.11. Russia

        17.11.1. Pricing Analysis

        17.11.2. Market Share Analysis, 2022

            17.11.2.1. By Technology

            17.11.2.2. By Product Type

            17.11.2.3. By Application 

            17.11.2.4. By End User

    17.12. Czech Republic

        17.12.1. Pricing Analysis

        17.12.2. Market Share Analysis, 2022

            17.12.2.1. By Technology

            17.12.2.2. By Product Type

            17.12.2.3. By Application 

            17.12.2.4. By End User

    17.13. Romania

        17.13.1. Pricing Analysis

        17.13.2. Market Share Analysis, 2022

            17.13.2.1. By Technology

            17.13.2.2. By Product Type

            17.13.2.3. By Application 

            17.13.2.4. By End User

    17.14. India

        17.14.1. Pricing Analysis

        17.14.2. Market Share Analysis, 2022

            17.14.2.1. By Technology

            17.14.2.2. By Product Type

            17.14.2.3. By Application 

            17.14.2.4. By End User

    17.15. Bangladesh

        17.15.1. Pricing Analysis

        17.15.2. Market Share Analysis, 2022

            17.15.2.1. By Technology

            17.15.2.2. By Product Type

            17.15.2.3. By Application 

            17.15.2.4. By End User

    17.16. Australia

        17.16.1. Pricing Analysis

        17.16.2. Market Share Analysis, 2022

            17.16.2.1. By Technology

            17.16.2.2. By Product Type

            17.16.2.3. By Application 

            17.16.2.4. By End User

    17.17. New Zealand

        17.17.1. Pricing Analysis

        17.17.2. Market Share Analysis, 2022

            17.17.2.1. By Technology

            17.17.2.2. By Product Type

            17.17.2.3. By Application 

            17.17.2.4. By End User

    17.18. China

        17.18.1. Pricing Analysis

        17.18.2. Market Share Analysis, 2022

            17.18.2.1. By Technology

            17.18.2.2. By Product Type

            17.18.2.3. By Application 

            17.18.2.4. By End User

    17.19. Japan

        17.19.1. Pricing Analysis

        17.19.2. Market Share Analysis, 2022

            17.19.2.1. By Technology

            17.19.2.2. By Product Type

            17.19.2.3. By Application 

            17.19.2.4. By End User

    17.20. South Korea

        17.20.1. Pricing Analysis

        17.20.2. Market Share Analysis, 2022

            17.20.2.1. By Technology

            17.20.2.2. By Product Type

            17.20.2.3. By Application 

            17.20.2.4. By End User

    17.21. GCC Countries

        17.21.1. Pricing Analysis

        17.21.2. Market Share Analysis, 2022

            17.21.2.1. By Technology

            17.21.2.2. By Product Type

            17.21.2.3. By Application 

            17.21.2.4. By End User

    17.22. South Africa

        17.22.1. Pricing Analysis

        17.22.2. Market Share Analysis, 2022

            17.22.2.1. By Technology

            17.22.2.2. By Product Type

            17.22.2.3. By Application 

            17.22.2.4. By End User

    17.23. Israel

        17.23.1. Pricing Analysis

        17.23.2. Market Share Analysis, 2022

            17.23.2.1. By Technology

            17.23.2.2. By Product Type

            17.23.2.3. By Application 

            17.23.2.4. By End User

18. Market Structure Analysis

    18.1. Competition Dashboard

    18.2. Competition Benchmarking

    18.3. Market Share Analysis of Top Players

        18.3.1. By Regional

        18.3.2. By Technology

        18.3.3. By Product Type

        18.3.4. By Application 

        18.3.5. By End User

19. Competition Analysis

    19.1. Competition Deep Dive

        19.1.1. Intrinsic LifeSciences

            19.1.1.1. Overview

            19.1.1.2. Product Portfolio

            19.1.1.3. Profitability by Market Segments

            19.1.1.4. Sales Footprint

            19.1.1.5. Strategy Overview

                19.1.1.5.1. Marketing Strategy

        19.1.2. Danaher Corporation (Beckman Coulter)

            19.1.2.1. Overview

            19.1.2.2. Product Portfolio

            19.1.2.3. Profitability by Market Segments

            19.1.2.4. Sales Footprint

            19.1.2.5. Strategy Overview

                19.1.2.5.1. Marketing Strategy

        19.1.3. Becton Dickinson and Company

            19.1.3.1. Overview

            19.1.3.2. Product Portfolio

            19.1.3.3. Profitability by Market Segments

            19.1.3.4. Sales Footprint

            19.1.3.5. Strategy Overview

                19.1.3.5.1. Marketing Strategy

        19.1.4. Akers Biosciences, Inc.

            19.1.4.1. Overview

            19.1.4.2. Product Portfolio

            19.1.4.3. Profitability by Market Segments

            19.1.4.4. Sales Footprint

            19.1.4.5. Strategy Overview

                19.1.4.5.1. Marketing Strategy

        19.1.5. Abbott Laboratories, Inc

            19.1.5.1. Overview

            19.1.5.2. Product Portfolio

            19.1.5.3. Profitability by Market Segments

            19.1.5.4. Sales Footprint

            19.1.5.5. Strategy Overview

                19.1.5.5.1. Marketing Strategy

        19.1.6. EDP Biotech Corporation

            19.1.6.1. Overview

            19.1.6.2. Product Portfolio

            19.1.6.3. Profitability by Market Segments

            19.1.6.4. Sales Footprint

            19.1.6.5. Strategy Overview

                19.1.6.5.1. Marketing Strategy

        19.1.7. Hologic (Gen-Probe)

            19.1.7.1. Overview

            19.1.7.2. Product Portfolio

            19.1.7.3. Profitability by Market Segments

            19.1.7.4. Sales Footprint

            19.1.7.5. Strategy Overview

                19.1.7.5.1. Marketing Strategy

        19.1.8. Biomérieux

            19.1.8.1. Overview

            19.1.8.2. Product Portfolio

            19.1.8.3. Profitability by Market Segments

            19.1.8.4. Sales Footprint

            19.1.8.5. Strategy Overview

                19.1.8.5.1. Marketing Strategy

        19.1.9. Bio-Rad Laboratories, Inc

            19.1.9.1. Overview

            19.1.9.2. Product Portfolio

            19.1.9.3. Profitability by Market Segments

            19.1.9.4. Sales Footprint

            19.1.9.5. Strategy Overview

                19.1.9.5.1. Marketing Strategy

        19.1.10. Thermo Fisher Scientific, Inc.

            19.1.10.1. Overview

            19.1.10.2. Product Portfolio

            19.1.10.3. Profitability by Market Segments

            19.1.10.4. Sales Footprint

            19.1.10.5. Strategy Overview

                19.1.10.5.1. Marketing Strategy

        19.1.11. Siemens Healthineers

            19.1.11.1. Overview

            19.1.11.2. Product Portfolio

            19.1.11.3. Profitability by Market Segments

            19.1.11.4. Sales Footprint

            19.1.11.5. Strategy Overview

                19.1.11.5.1. Marketing Strategy

        19.1.12. Quidel Corporation

            19.1.12.1. Overview

            19.1.12.2. Product Portfolio

            19.1.12.3. Profitability by Market Segments

            19.1.12.4. Sales Footprint

            19.1.12.5. Strategy Overview

                19.1.12.5.1. Marketing Strategy

20. Assumptions & Acronyms Used

21. Research Methodology

Recommendations

Healthcare

Radioimmunoassay Market

June 2023

REP-GB-1196

221 pages

Healthcare

Immunoassay Market

October 2022

REP-GB-15437

342 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Neuro Immunoassay Market

Schedule a Call